12:00 AM
Nov 02, 2015
 |  BioCentury  |  Finance

Same name, different dollars

Why Frazier's new fund is life science-only

After nearly 25 years, Frazier Healthcare is separating its life sciences venture investments from its growth buyouts. Both groups will still operate under the Frazier name, but the new $262 million Frazier Life Sciences VIII fund will have only two managing general partners calling the shots.

Within life sciences, the firm isn't changing its strategy of investing in therapeutics. Frazier expects to make a total of about 15 investments from the new fund, which closed last week.

"We spent a lot of time thinking about what's right for our businesses, and about 90% of our LP base fully understood this and was supportive of the approach," said Frazier's Patrick Heron. "There's 10% who...

Read the full 559 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >